品名
货号
CAS号
描述
品牌
全部
Lenalidomide hemihydrate (CC-5013 hemihydrate) 是 Thalidomide 的衍生物,也是一种具有口服活性免疫调节剂,以分子胶的方式作用。Lenalidomide hemihydrate (CC-5013 hemihydrate) 是一种泛素 E3 连接酶 cereblon (CRBN) 的配体,通过 CRBN-CRL4 泛素连接酶对两种淋巴转录因子 IKZF1 和 IKZF3 进行选择性泛素化和降解。Lenalidomide hemihydrate (CC-5013 hemihydrate) 特别地抑制成熟 B 细胞淋巴瘤 (包括多发性骨髓瘤) 的生长,并诱导 T 细胞释放白细胞介素-2 (IL-2)。
生物活性
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
IC50 & Target[5]
Cereblon
体外研究 (In Vitro)
Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells[2]. Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC50 values of ~30?μM, ~3?μM and ~3?μM, respectively, These reduced CRBN expression cells (U266-CRBN60 and U266-CRBN75) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10?μM[3]. Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation[5].
体内研究 (In Vivo)
The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes[4].
Clinical Trial
NCT Number
Sponsor
Condition
Start Date
Phase
NCT00751296
University Health Network, Toronto|Celgene
Chronic Lymphocytic Leukaemia
August 2006
Phase 2
NCT01675141
National Cancer Institute (NCI)|Celgene Corporation|National Institutes of Health Clinical Center (CC)
Multiple Myeloma
August 20, 2012
NCT02160015
National Cancer Institute (NCI)
Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
May 9, 2014
Phase 1
分子量
268.27
Formula
C??H??N?O?.?
CAS 号
847871-99-2
中文名称
来那度胺半水合物;雷那度胺半水合物
SMILES
O=C1N(C2C(NC(CC2)=O)=O)CC3=C(N)C=CC=C31.[0.5 H2O]
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
1 month
溶解性数据
In Vitro:
DMSO : 50 mg/mL (186.38 mM; Need ultrasonic)
H2O : 0.1 mg/mL (0.37 mM; Need ultrasonic)
配制储备液
浓度溶剂体积质量
1 mg
5 mg
10 mg
1 mM
3.7276 mL
18.6379 mL
37.2759 mL
5 mM
0.7455 mL
7.4552 mL
10 mM
0.3728 mL
1.8638 mL
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
1.请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
2.请依序添加每种溶剂: 10% DMSO 90% (20% SBE-β-CD in saline)
3.请依序添加每种溶剂: 10% DMSO 90% corn oil
参考文献
[1]. Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.
[2]. Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.
[3]. Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.
[4]. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35.
[5]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82.
聚光科技
北京吉天
仪器信息网
化工仪器网
中国分析测试协会
中国自动化网
中国药物分析网
中国分析仪器网
中国实验室管理网
生物谷
丁香园
中国色谱网
检验天空网
中国教育装备采购网
仪器仪表交易网
中国颗粒学会
生物器材网
中国测控网
食品商务网
中国热处理网
中国质谱学会
食品伙伴网
中国自控网
中国水工业网
Sigma-Aldrich
Merck
首 页 | 公司简介 | 客户服务 | 联系我们 | 常见问题 | 投诉与建议
沪ICP备 08012727 ><!-- Inject Script Filtered -->